Sandoz is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering patient access. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. It's a leading portfolio of approximately 1,300 products that addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world's first oral penicillin in 1951, and the world's first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.

Sandoz in India
India is a key pillar in Sandoz's global network, with over 2,200 associates working across three major business units:

• Sandoz Technical (Global Manufacturing & Supply) – Kalwe, Maharashtra
  
• Sandoz Development Centre (R&D) – Hyderabad
  
• Sandoz Global Competency Centre (Shared Services) – Hyderabad
  

Sandoz India plays a strategic role in global manufacturing, research, development, and shared services—helping expand access to high-quality, affordable medicines for patients around the world.